Retrospective study evaluating the safety of administering pegfilgrastim on the final day of 5-fluorouracil continuous intravenous infusion.
| Autor: | Draper, Amber S, Lafollette, Jennifer, Kim, Chaejin, Wu, Christina S |
|---|---|
| Předmět: |
PANCREATIC tumors
INTRAVENOUS therapy GRANULOCYTE-colony stimulating factor ACQUISITION of data methodology FEBRILE neutropenia CONFIDENCE intervals RETROSPECTIVE studies NEUTROPENIA DISEASE incidence FLUOROURACIL GASTROINTESTINAL tumors COLORECTAL cancer RISK assessment TREATMENT delay (Medicine) TREATMENT effectiveness MEDICAL records DESCRIPTIVE statistics DRUG therapy DISEASE risk factors |
| Zdroj: | Journal of Oncology Pharmacy Practice; Jul2021, Vol. 27 Issue 5, p1159-1164, 6p |
| Abstrakt: | Background: Pegfilgrastim, a long-acting granulocyte-colony-stimulating factor used to prevent neutropenia, is not indicated for administration within 24 h of completion of chemotherapy. The safety of administering pegfilgrastim in gastrointestinal cancer chemotherapy regimens containing continuous intravenous infusion of 5-fluorouracil (5-FUCI) on the day of completion of 5-fluorouracil has not been adequately studied. Methods: An institutional review board-approved retrospective analysis of patients with a gastrointestinal malignancy receiving pegfilgrastim on the final day of 5-FUCI was conducted. The primary end point was to determine the incidence of grade 3 and grade 4 neutropenia and febrile neutropenia when pegfilgrastim was administered on the final day of 5-FUCI. The secondary endpoint was to determine rate of dose reductions and treatment delays. Results: A total of 300 patients were reviewed from January 2010 to May 2017. The most common cancers were colorectal (25%) and pancreatic (60%), with 77% of patients having late stage disease. The risk of a patient developing grade 3 neutropenia was 0.010 (95% CI 0.002–0.029) and grade 4 neutropenia was 0.007 (95% CI 0.001–0.024). The risk of febrile neutropenia was 0.007 (95% CI 0.001–0.024). The risks of treatment delay and treatment reduction were 0.013 (95% CI 0.004–0.034) and 0.010 (95% CI 0.002–0.029), respectively. Conclusion: The low risk of grade 3 and grade 4 neutropenia, febrile neutropenia, as well as dose delays and/or reduction suggests that pegfilgrastim can be administered on the final day of 5-FUCI. Limitations of this study were that it was retrospective in nature and was conducted at a single institution. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|